The winner of the first HCA Award is Dr Michael Freeley from the Institute of Molecular Medicine, Trinity College Dublin (TCD), who investigates how white blood cells (T lymphocytes) move in the body during an immune response. Movement of T lymphocytes from the blood stream into target tissues is crucial in an effective immune response against disease-causing organisms, but unregulated migration of T lymphocytes is also a major contributor to auto-immune diseases such as multiple sclerosis, Crohn’s disease and rheumatoid arthritis. A better understanding of this process could ultimately lead to treatments that selectively block this migration in these diseases.
Dr Freeley and his co-researchers, including some from the National Centre for HCA at TCD, used the IN Cell Analyzer from GE Healthcare to measure a wide range of morphology and fluorescence parameters associated with signaling pathways and proteins that regulate T lymphocyte migration. This is allowing them to define the crucial proteins much more rapidly and providing an easy, interpretable screen from complicated morphology readouts. They also demonstrated that measuring multiple parameters increased the sensitivity of hit selection, which helps in reducing the number of false positives.
“We are delighted to receive the first HCA Award,” said Dr Michael Freeley. “Quite simply, the scale of work that we performed could not have been done by manual means, and we estimate that the HCA approach has increased our throughput at least 20-fold. Capturing the same number of fields manually would have taken in the region of 400 hours instead of 20 hours, with the IN Cell Analyzer image analysis software saving us a considerable amount of time.”
“The excellent quality of the entries certainly made judging difficult,” said Dr Joe Trask, Head of Cellular Imaging Core at Hamner Institutes of Health Services, and a member of the judging panel. “The winning entry showcased the immensely positive impact of HCA on research today and demonstrated how the IN Cell Analyzer’s technology saved invaluable time to produce high quality scientific data that, crucially, was also publishable.”
“This multiparameter approach has great potential to increase insights in a wide range of chemical and RNA inhibition screens” added Dr Nick Thomas, Principal Scientist at GE Healthcare Life Sciences, and member of the judging panel.
Entries were welcomed from scientists using IN Cell Analyzers. Entries were reviewed by an expert scientific panel comprising Dr Joe Trask, Head of Cellular Imaging Core at Hamner Institutes of Health Services, Dr Nick Thomas, Principal Scientist, Cell Technologies, GE Healthcare and Dr Patrick Lo, Associate Editor, BioTechniques. The HCA Award will be presented to Dr Michael Freeley and his co-author Dr Dara Dunican, at the 50th American Society of Cell Biology Annual Meeting in Philadelphia.
For more information about the HCA award please visit: www.gelifesciences.com/hcaaward
About the winning research:
Dr Michael Freeley worked on the research with Dr Dara Dunican (lead authors), in association with Mr Gabor Bakos (TCD), Dr Anthony Davies (National Centre for HCA in TCD), Prof Dermot Kelleher (Director of the Institute of Molecular Medicine, TCD) and Dr Aideen Long (Principal Investigator and Senior Lecturer, TCD). The group’s research has been published in the following journal:
Freeley et al. Journal of BioMolecular Screening (2010) 15(5): 541-555 http://jbx.sagepub.com/content/15/5/541.full
About GE Healthcare:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $16 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Contact College Hill Lynne Trowbridge, Tim Watson +44 (0)20 7866 7861 ge-celltechnologies@collegehill.com
